Recently, immune checkpoint inhibitors (ICIs), particularly programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, have shown antitumoral activity in patients with advanced ESCC. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.